Kolon Life Science’s osteoarthritis therapy ‘Invossa K’ landed in 60 general hospitals

Published: 2018-06-14 16:27:00
Updated: 2018-06-14 16:36:05

‘Invossa,’ a gene therapy for osteoarthritis, will start to be prescribed in general hospitals.

Kolon Life Science(CEO Woo-Seok Lee) and Mundipharma(CEO Myung-Sae Lee) announced on the 11th that the world’s first and only ‘Invossa® K’ passed 60 major general hospitals’ drug committee as well as ...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.